Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Nov 19, 2024
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma multiforme (GBM) -
Read more at globenewswire.comNASDAQ:DRTSW (5/30/2025, 8:00:01 PM)
0.21
-0.04 (-16%)
NASDAQ:DRTS (5/30/2025, 8:00:01 PM)
2.985
-0.02 (-0.5%)
Find more stocks in the Stock Screener
